Search

Indeed, in literature there are studies that have not shown superiority of secukinumab and ixekizumab compared with adalimumab on PsA according to ACR20.6 Hence, treating algorithm selection in PsA patients maybe not always easy. Psoriasis has a prevalence of 2%-4% in western adults, and 20%-30% of psoriasis patients may develop psoriatic arthritis (PsA).1 PsA is an inflammatory musculoskeletal disease, affecting both men and women and usually following psoriasis development; hence PsA screening questionnaires are frequently used for a prompt diagnosis.2 It is a complex disease that affects multiple organ systems including peripheral and axial joints, entheses, skin, and nails. [Extracted from the article]

Simple Summary: Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the commonest types of non-melanoma skin cancer. Surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients' comorbidities may limit the use of these techniques, making the treatment challenging. The introduction of oral therapies targeting a pathogenetic pathway in BCC has revolutionized the therapeutic scenario. However, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients' comorbidities may limit the use of these techniques, making the treatment challenging. As regards BCC, even if hedgehog inhibitors revolutionized the therapeutic scenario, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Different specialists including oncologists, radiologists, dermatologists, and surgeons are required to guarantee an integrated approach, leading to the best management of patients. Moreover, the collaboration among specialists will allow them to best manage the TEAEs, reducing the risk of treatment suspension or discontinuation. Certainly, ongoing studies and more and more emerging real-world evidence, will allow us to better characterize the role of cemiplimab for the management of advanced non-melanoma skin cancer. [ABSTRACT FROM AUTHOR]

Risankizumab is a humanized IgG monoclonal antibody inhibitor of IL23 and has been recently approved by the EMA and the FDA for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Its efficacy and safety have been reported by clinical trials and real-life studies. However, even if long-term data from trials have already been reported (up to 172 weeks), data on long-term real-life experiences are still limited. The aim of our study was to investigate the long-term (2 years) efficacy and safety of risankizumab for psoriasis management in a real-life setting. A monocentric retrospective study was performed, enrolling 168 patients affected by moderate to severe psoriasis who were undergoing treatment with risankizumab. Psoriasis severity and safety outcomes were evaluated at each follow-up visit (week 16, week 28, week 52, week 88, week 104). A statistically significant reduction of psoriasis severity scores was reported from week 16 and was maintained up to week 104. Moreover, interesting results in terms of safety have been collected, without any serious adverse events registered. Our long-term real-life monocentric retrospective study confirmed the efficacy and safety of risankizumab up to 104 weeks of treatment. However, further studies are required to confirm our results and to increase available data to establish the best evidence-based biologic selection algorithm. [ABSTRACT FROM AUTHOR]

Several cutaneous reactions to Moderna (83%) or Pfizer (17%) COVID-19 vaccines were reported by McMahon et al. for 414 unique patients.1 The most common cutaneous reaction was delayed large local reaction, followed by local injection site reactions, urticaria, morbilliform eruptions, erythromelalgia, and pernio/chilblains. Dear Editor In December 2020 the FDA authorized Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines. We report two cases of "COVID arm": a localized erythematous reaction at the injection site after the first administration of Moderna COVID-19 vaccine.2 None of them had COVID-19 infection symptoms prior to their COVID-19 vaccinations and the onset of their skin rash. [Extracted from the article]

Epidemiological studies suggest a reduction in the risk of cardiovascular events in populations that drink five or more cups of tea a day. In a randomized, double-blind placebo controlled trial, we examined the effect of a standardized formula made from Camellia sinensis (green tea) on biomarkers of inflammation and blood pressure. Serum amyloid-α (SAA) is an acute phase reactant that is positively associated with coronary artery disease. Consumption of this green tea formula (GTF) for 3 weeks resulted in a 42% reduction from baseline SAA levels in the treated group (p=0.041), while SAA levels of those on the placebo did not change (p=0.561). Of 52 subjects on GTF, 39 (75%) had a reduced SAA levels while the values of 13 (25%) increased or remained the same. Of 56 subjects on placebo, 31 (55%) showed a decrease in SAA levels and 25 (45%) went up or stayed the same (p=0.049). Subjects consuming GTF for 3 weeks had lower systolic (-4.2; p=0.004), and diastolic (-4.2; p=0.001) blood pressure. Placebo subjects had no significant change in blood pressure. In conclusion, consumption of this GTF resulted in lowering of blood pressure, and an inflammatory biomarker associated with cardiovascular disease. Funded in part by UF/IFAS AES, Nature Trade Center, Inc., and Taiyo International, Inc. [ABSTRACT FROM AUTHOR]